Ramm Pharma (RAMM) AI Stock Analysis

• Market Cap: C$1.79M
• Dividend Yield: N/A
• Average Volume (3M): 20.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.77
• Revenue Growth: -15.51%
• EPS Growth: -49.26%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 119,389,320
• 10 Day Avg. Volume: 1,800
• 30 Day Avg. Volume: 20,847
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Ramm Pharma's overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and cash flow issues. While technical indicators suggest some positive momentum, the high volatility and negative valuation metrics further weigh down the score.

Ramm Pharma Business Overview & Revenue Model

Company Description

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.

How the Company Makes Money

Ramm Pharma generates revenue primarily through the sales of its proprietary drug products and formulations. The company also benefits from licensing agreements with larger pharmaceutical firms, wherein it licenses its technology or product candidates in exchange for upfront payments, royalties, and milestone payments based on the progression of the drug through various stages of development. Additionally, Ramm Pharma may engage in partnerships for collaborative research and development projects, allowing it to share costs and tap into the distribution networks of established partners, thereby expanding its market reach and revenue potential.

Ramm Pharma Financial Statement Overview

Summary

Ramm Pharma is facing significant financial difficulties. The company struggles with operational losses and cash flow constraints, as evidenced by a negative net income of -$13.7M and negative free cash flow. Despite a solid equity position with low debt, the ongoing losses and liquidity challenges present substantial risks.

Income Statement

Ramm Pharma's income statement reveals significant challenges. The TTM data shows a negative net income of -$13.7M, indicating substantial losses. The gross profit margin is approximately 36.8%, which is decent but overshadowed by negative EBIT and EBITDA margins, suggesting operational inefficiencies. Revenue has decreased from the previous period, indicating a contraction in sales growth. Overall, the company struggles with maintaining profitability and growth.

Balance Sheet

The balance sheet shows a relatively strong equity position with stockholders' equity making up over 81.9% of total assets. The debt-to-equity ratio is very low at 0.0034, indicating limited reliance on debt. However, the company faces liquidity challenges with a shrinking cash position. While the low leverage is a strength, the declining asset base and equity value pose risks.

Cash Flow

Ramm Pharma's cash flow statement highlights cash management issues. The company has a negative free cash flow of -$2.5M in the TTM, showing a high cash burn rate. The operating cash flow to net income ratio is negative, reflecting poor cash generation from operations. Overall, the company faces substantial cash flow challenges, impacting its ability to invest and sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.34M	5.07M	3.90M	4.12M	5.44M
Gross Profit	1.76M	381.82K	530.50K	-7.64K	1.28M
EBITDA	-15.23M	-6.30M	-19.91M	-6.36M	-6.91M
Net Income	-16.50M	-7.72M	-20.96M	-7.11M	-7.43M
Balance Sheet
Total Assets	16.75M	32.30M	39.31M	59.71M	37.17M
Cash, Cash Equivalents and Short-Term Investments	814.04K	5.12M	9.77M	17.16M	28.01M
Total Debt	188.31K	405.14K	683.70K	32.16K	100.43K
Total Liabilities	3.11M	2.84M	3.72M	3.32M	1.34M
Stockholders Equity	13.63M	29.46M	35.59M	56.39M	35.84M
Cash Flow
Free Cash Flow	-4.05M	-4.45M	-6.08M	-4.25M	-4.80M
Operating Cash Flow	-4.00M	-4.34M	-5.91M	-3.82M	-2.91M
Investing Cash Flow	-47.43K	126.58K	-1.15M	-6.83M	-1.56M
Financing Cash Flow	-258.23K	-409.97K	-353.77K	-190.33K	-2.91M

Ramm Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.24 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RAMM	44 Neutral	C$1.79M	―	-69.77%	―	-15.51%	-49.26%
OVAT	39 Underperform	C$881.12K	―	―	―	-36.47%	34.50%
PHRX	29 Underperform	C$1.08M	―	―	―	―	98.74%

Ramm Pharma Corporate Events

RAMM Pharma Explores Sale of Italian Subsidiary Canapar

RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.